ClinicalTrials.gg
CompletedNCT01968044GUARDUpdated Mar 23, 2016

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

A Phase 3 interventional study of Gemigliptin and Placebo to Linagliptin in Type 2 DM Patients With Moderate or Severe Renal Impairment, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Renal Insufficiency with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency · Korea, Republic of.

Enrollment
17th of 29
132 · median 209
Started
2013
with 2 others
Phase 3
9 of 35
none open now
Registered
17th of 35
by date

Among the 35 studies in Renal Insufficiency with a site in Korea, Republic of, this one is the 17th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 17th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

4 of the 35 studies in Renal Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Renal Insufficiency with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor gemigliptin in patients with type 2 DM and moderate or severe renal impairment for long-term peirod (52 weeks).

03

Conditions studied

  • Type 2 DM Patients With Moderate or Severe Renal Impairment

Browse trials for

Keywords

  • renal impairment
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 2 Diabetes Mellitus
  • Patients with moderate or severe renal insufficiency
  • All patients give written

Exclusion criteria

Exclusion Criteria:

  • Has type 1 diabetes mellitus or a history of ketoacidosis
  • Is on dialysis or is likely to need dialysis during the study
  • Has active liver disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Gemigliptin

    Participant will remain gemigliptin 50mg throughout entire study (52 weeks).

    Drug: Gemigliptin

  • Other
    Placebo to linagliptin

    Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.

    Drug: Placebo to Linagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c change

    Time frame: HbA1c change from baseline to week 12

Secondary outcomes

  1. HbA1c Change

    Time frame: HbA1c change from baselint to week 6, 52

  2. FPG

    Time frame: FPG change from baseline to week 6,12,52

  3. Glycated albumin

    Time frame: Glycated albumin change from baseline to week 6,12,52

  4. Fructosamin

    Time frame: Fructosamin change from baseline to week 6,12,52

  5. Waist

    Time frame: Waist change from baseline to week 12,52

  6. HbA1c responser (HbA1c<7.0%)

    Time frame: HbA1c responser rate at week 12,52

  7. Fasting serum C-peptide

    Time frame: Fasting serum C-peptide change from baseline to week 12,52

  8. Fasting Lipid parameters

    Time frame: Fasting Lipid parameters change from baseline to week 12,52

  9. Albuminuria

    Time frame: Albuminuria change from baseline to week 12,52

07

Study locations

1 site
  • Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Oct 23, 2013
Start
Oct 2013
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Last update
Mar 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01968044
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Oct 23, 2013
Start date
Oct 2013
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Mar 23, 2016

Study contacts

DR Cha, MD, Ph.D
principal investigator · Korea University Ansan Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion